Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease

Biomedicine and Pharmacotherapy

Volumn 64, Issue 5, 2010, Pages 339-342

  Dini, Frank Lloyd ^a   Buralli, Simona ^b   Bajraktari, Gani ^c   Elezi, Shpend ^c   Duranti, Emiliano ^b   Metelli, Maria Rita ^b   Carpi, Angelo ^b   Taddei, Stefano ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

Author keywords

Echocardiography; Heart failure; Metalloproteinases; Natriuretic peptides

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; LOOP DIURETIC AGENT; STROMELYSIN;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOPPLER ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; SYSTOLIC HEART FAILURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 77953285276     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.09.008     Document Type: Article

References (20)

1. Lloyd-Jones D.M., Larson M.G., Leip E.P., Beiser A., D'Agostino R.B., Kannel W.B., et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure. Circulation 2002, 106:3068-3072.
2. Green S.M., Green J.A., Jannuzzi J.L. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting. Am J Ther 2009, 16:171-177.
3. Lee D.S., Vasan R.S. Novel markers for heart failure diagnosis and prognosis. Curr Opinion Cardiol 2005, 20:201-210.
4. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
5. Nagueh S., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22:107-133.
6. McDermott M.M., Feinglass J., Lee P.I., Metha S., Schmitt B., Lefevre F., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997, 134:728-736.
7. Solomon S.D., Skali H., Anavekar N.S., Bourgoun M., Barvik S., Ghali J.K., et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005, 111:3411-3419.
8. Squire IB, Evans J, NG LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohormonal parameters of left ventricular dysfunction. J Card Fail 2004;10:328-33.
9. Yun Y.L., McTiernan C.F., Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000, 46:214-224.
10. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
11. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley J.C., Spinale F.G. Increased matrix metalloproteinases activity and selective upregulation in left ventricular myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708-1715.
12. Spinale F.G., Coker M.L., Krombach S.R., Mukherjee R., Hallak H., Houck W.V., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Cir Res 1999, 85:364-376.
13. Peterson J.T., Dillon L., Bryant J.W. Evolution of metalloproteinase and tissue inhibitor expression during heart failure progression in the infracted heart. Cardiovasc Res 2000, 46:307-315.
14. Wagner R.D., Delagardelle C., Ernens I., Rouy D., Vaillant M., Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Cardiac Fail 2006, 12:66-72.
15. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., et al. Plasma matrix metalloproteinase-9 and left ventricular remodeling after acute myocardial infarction in man. Eur Heart J 2007, 28:718-771.
16. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: The Framingham Heart Study. Circulation 2004, 109:2850-2856.
17. George J., Patal S., Wexler D., Roth A., Sheps D., Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005, 150:484-487.
18. Tziakas D.N., Chalikias G.K., Papaioakeim M., Hatzinikolaou E.I., Stakos D.A., Tentes I.K., et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 2005, 96:1449-1451.
19. Ohtsuka T., Nishimura K., Kurata A., Ogimoto A., Okayama H., Higaki J. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Cardiac Fail 2007, 13:752-758.
20. Vorovich E.E., Chuai S., Li M., Averna J., Marwin V., Wolfe D., et al. Comparison of matrix metalloproteinase-9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J 2008, 155:992-997.